2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Paul L. Nguyen, MD, discusses future research in high-risk prostate cancer.
Paul L. Nguyen, MD, senior physician and director of Genitourinary Clinical Center for Radiation Oncology at Dana-Farber Cancer Institute, and a professor of radiation oncology at Harvard Medical School, discusses future research in high-risk prostate cancer.
Future research efforts in high-risk prostate cancer should focus on personalizing therapy for patients, says Nguyen. For example, a one-size-fits-all approach is currently utilized with androgen deprivation therapy.
As such, the field is anticipating results from the phase 3 Predict-RT trial, which will use genomics to assist in the personalization of therapy for patients, explains Nguyen.
Additionally, future research efforts are focused on minimizing the adverse effects associated with hormone therapy by using genomic markers to inform deintensification strategies. Both emerging approaches continue to garner significant excitement in the space, Nguyen concludes.